AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm announced the commencement of a rights offering today, coinciding with an investor webinar. The central question for stakeholders is whether the targeted capital will be sufficient to advance the company’s lead drug candidate, Ampligen, through its ambitious trial objectives.

Concurrently with the offering, company management is hosting a conference to update investors on clinical progress, particularly for the DURIPANC Phase 2 study. This trial is evaluating Ampligen in combination with AstraZeneca’s immunotherapy drug, Imfinzi, as a treatment for metastatic pancreatic cancer.